Progress in efficacy and safety of vigabatrin in treatment of epilepsy associated with tuberous sclerosis complex in children / 国际儿科学杂志
International Journal of Pediatrics
; (6): 302-305, 2023.
Article
in Zh
| WPRIM
| ID: wpr-989085
Responsible library:
WPRO
ABSTRACT
Tuberous sclerosis complex(TSC)is an autosomal dominant skin-nerve syndrome with diverse clinical manifestations.Epilepsy is the most common neurological manifestation.Vigabatrin(VGB)is an inhibitory neurotransmitter γ-aminobutyric acid(GABA)analogue.It reduces the degradation of GABA by irreversibly binding to GABA transaminase, thereby increasing the level of GABA in the central nervous system and exerting anti-epileptic effects.It is suitable for the treatment of various types of epilepsy related to TSC.In recent years, the preventive effect of VGB in TSC-related epilepsy has attracted wide attention.There is a certain degree of adverse reactions during the use of VGB, the most noteworthy of which is the visual field and central nervous system changes.This article reviews the efficacy and safety of VGB in the treatment of TSC-related epilepsy.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
International Journal of Pediatrics
Year:
2023
Type:
Article